Dr. Ryan W. Jacobs, MD

Medicare patients and services

Medicare patients, 2024

175

Services billed

567

Patients’ average age

73

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 14 companies reported 297 payments worth $218,561 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in North Carolina →

Industry-funded research

Named as a principal investigator on 14 industry-funded studies in 2025, from 7 companies. The companies reported $2,655,474 in research payments for these studies, mostly to the institutions running them.

• A phase 3 prospective,multicenter,randomized,open label trial of acalabrutinib plus venetoclax versus venetoclax plus obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma
  AstraZeneca UK Limited
• Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
  Beigene, Ltd. · Active, not recruiting · NCT06073821
• A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
  Eli Lilly and Company · Active, not recruiting · NCT04965493
• A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
  Beone Medicines Ltd. · Recruiting · NCT06742996
• A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
  Regeneron Pharmaceuticals, Inc. · Recruiting · NCT06091254
• Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
  AbbVie Inc. · Active, not recruiting · NCT05618028
• A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
  Beone Medicines Ltd. · Recruiting · NCT06943872
• A phase 3 open-label, randomized study of LOXO-305 versus investigator choice of btk inhibitor in patients with previously treated btk inhibitor naive mantle cell lymphoma (bruin MCL-321)
  Eli Lilly and Company
• Chronic Lymphocytic Leukemia (CLL)
  AstraZeneca Pharmaceuticals LP
• A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
  AbbVie Inc.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Hematology clinicians in Charlotte

• Belinda R. Avalos, MD
• Manisha Bhutani, MD
• Landon C. Brown, MD
• Earle F. Burgess III, MD
• Aleksander L. Chojecki, MD
• Edward A. Copelan, MD
• Payal C. Desai, MD
• Omotayo O. Fasan, MBBS